Blood typing has become a routine test item of clinical blood transfusion department and clinical laboratory, which includes ABO blood group, Rh blood group, and cross-matching of blood test.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

2021 ranking features 143 Chinese companies, 122 U.S. companies, and 53 Japanese companies. 6 in vitro diagnostic companies on the list.

On August 3, Sinopharm listed its 30% equity interest in Maixin Biotechnology on the China Beijing Equity Exchange at a price of 947.5 million yuan. Beijing Strong Biotechnologies, Inc. (hereinafter referred to as BSBE) said they would fight for the acquisition.

DiaSorin said on Friday that its second quarter revenues rose 20 percent year over year, driven by strength in molecular diagnostic test sales.

On July 28, 2021, Thermo Fisher Scientific announcing that it would invest in the construction of another brand-new factory under Thermo Fisher China manufacturing center in Suzhou High Tech Zone. The total investment is $50 million, which is expected to be completed and put into use in 2022.

PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today reported financial results for the second quarter ended July 4, 2021.

PerkinElmer, Inc. (NYSE: PKI) (“PerkinElmer”) today announced it has entered into an agreement to acquire BioLegend, a leading, global provider of life science antibodies and reagents, for approximately $5.25 billion in a combination of cash and stock, subject to certain adjustments.

On July 25, 2021, Autobio and Syscan officially announced the launch of a strategic cooperation. In the future, the two companies will make full use of their respective technology and channel advantages to carry out a full range of in-depth cooperation in the field of coagulation testing.

July 22, Roche reported a 51 percent increase in half-year revenues for its Diagnostics division, largely thanks to demand for its COVID-19 products.

Danaher reported before the opening of the market on Thursday that its second quarter revenues rose 37 percent year over year, thanks largely to steep gains from its life sciences and diagnostics businesses.

July 22, Abbott said that its Diagnostics business revenues grew 63 percent year over year in the second quarter, while its total revenues were up 39 percent.